This is a multicenter, prospective, observational investigation, focusing of antiplatelet treatment in patients with moderate to high risk acute coronary syndrome (TIMI risk score ≥3)subjected to percutaneous coronary intervention (PCI), being conducted in 7 PCI capable hospitals in Greece. Data concerning patients' demographic, clinical/procedural characteristics and contraindications/special warnings and precautions to P2Y12 inhibitors are collected during initial hospitalization. Study involves 3 follow-up visits after hospital discharge(Day 30, at 6 months and at 12 months) where data on major adverse cardiac events (death, myocardial infarction, stroke, urgent revascularization procedure with PCI or CABG), bleeding events(according to Bleeding Academic Research Consortium criteria)and adherence to antiplatelet treatment are collected. In patients under ticagrelor or prasugrel treatment, platelet reactivity measurement with VerifyNow assay will be performed at Day 30
Study Type
OBSERVATIONAL
Enrollment
2,047
Patras University Hospital
Pátrai, Achaia, Greece
G.Gennimatas General Hospital
Athens, Attica, Greece
University Hospital, Alexandroupolis
Alexandroupoli, Greece
1st Department of Cardiology, Ippokration Hospital
Athens, Greece
Alexandra Hospital, Athens, Greece
Athens, Greece
Onassis Cardiac Surgery Center
Athens, Greece
University Hospital, Ioannina
Ioannina, Greece
Iraklion University Hospital, Iraklion, Greece
Irakleio, Greece
Larissa University Hospital
Larissa, Greece
MACES at 12 months following PCI
The composite of death, myocardial infarction, stroke, urgent revascularization procedure with PCI or CABG at 12 months after PCI
Time frame: 12 months
Any bleeding event (BARC classification) at 12 months after PCI
Any bleeding event (BARC classification) at 12 months after PCI
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.